NCT04256317 2026-03-18
A Multi-phase Study of ASTX030 (Azacitidine and Cedazuridine) in Myeloid Neoplasm Alone or in Combination With Venetoclax in AML (AZTOUND Study)
Taiho Oncology, Inc.
Phase 2/3 Recruiting
Clinical Trials
9 trialsNCT04708054 2026-02-19
Venetoclax to Improve Outcomes of Fractionated Busulfan Regimen in Patients With High-Risk AML and MDS
M.D. Anderson Cancer Center
Phase 2/3 Recruiting
NCT07366801 2026-01-26
Co-infusion of Treg-enriched Donor Lymphocytes With CD3-depleted Hematopoietic Stem Cell Graft to Prevent Graft-versus Host Disease After Allogeneic Hematopoietic Stem Cell Transplantation Among Children With Hematologic Malignancies
Federal Research Institute of Pediatric Hematology, Oncology and Immunology
Phase 2/3 Recruiting
NCT06788756 2025-12-16
L-Annamycin for Injection in Combination With Cytarabine Injection as Second Line Therapy for Remission Induction in Adult Subjects With Refractory/Relapsed AML
Moleculin Biotech, Inc.
Phase 2/3 Recruiting
NCT02416388 2024-08-07
BIG-1
University Hospital, Angers
Phase 2/3 Recruiting
NCT05939180 2024-04-09
VA vs DA for Newly Diagnosed Hig-risk AML
The First Affiliated Hospital of Soochow University
Phase 2/3 Recruiting
NCT05805098 2023-04-07
VHA
The First Affiliated Hospital of Soochow University
Phase 2/3 Recruiting
NCT05404906 2022-08-19
AZA + Venetoclax as Maintenance Therapy in Younger Adults With AML in First Remission
The First Affiliated Hospital of Soochow University
Phase 2/3 Recruiting
NCT03793517 2020-03-10
Decitabine Plus mBU/CY for High Risk Acute Leukemia With MRD Pre-HSCT
Peking University People's Hospital
Phase 2/3 Recruiting